Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus
Novo Nordisk A/S Class B shares closed higher on Friday in Copenhagen and head into the new week on that note, boosted by early signs of strong demand for its Wegovy weight-loss drug.
